Literature DB >> 25574627

Biosimilars or semi-similars?

Huub Schellekens1, Ellen Moors1.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 25574627     DOI: 10.1038/nbt.3083

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Amgen best-seller challenged by generics.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2013-09       Impact factor: 54.908

  1 in total
  4 in total

1.  Celltrion's infliximab copy shows path to biosimilars in US.

Authors:  Eva von Schaper
Journal:  Nat Biotechnol       Date:  2016-05-06       Impact factor: 54.908

Review 2.  High-Resolution Native Mass Spectrometry.

Authors:  Sem Tamara; Maurits A den Boer; Albert J R Heck
Journal:  Chem Rev       Date:  2021-08-20       Impact factor: 72.087

3.  Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices.

Authors:  Hans C Ebbers; Paul Chamberlain
Journal:  BioDrugs       Date:  2016-02       Impact factor: 5.807

4.  Direct quality control of glycoengineered erythropoietin variants.

Authors:  Tomislav Čaval; Weihua Tian; Zhang Yang; Henrik Clausen; Albert J R Heck
Journal:  Nat Commun       Date:  2018-08-21       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.